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ABSTRACT
Background. Most genetic disorders are caused by single nucleotide variations
(SNVs) or small insertion/deletions (indels). High throughput sequencing has
broadened the catalogue of human variation, including common polymorphisms,
rare variations or disease causing mutations. However, identifying one variation
among hundreds or thousands of others is still a complex task for biologists, geneti-
cists and clinicians.
Results. We have developed VaRank, a command-line tool for the ranking of genetic
variants detected by high-throughput sequencing. VaRank scores and prioritizes
variants annotated either by Alamut Batch or SnpEff. A barcode allows users to
quickly view the presence/absence of variants (with homozygote/heterozygote status)
in analyzed samples. VaRank supports the commonly used VCF input format for
variants analysis thus allowing it to be easily integrated into NGS bioinformatics
analysis pipelines. VaRank has been successfully applied to disease-gene identifica-
tion as well as to molecular diagnostics setup for several hundred patients.
Conclusions. VaRank is implemented in Tcl/Tk, a scripting language which is
platform-independent but has been tested only on Unix environment. The source
code is available under the GNU GPL, and together with sample data and detailed
documentation can be downloaded from http://www.lbgi.fr/VaRank/.
Subjects Bioinformatics, Genetics, Genomics
Keywords Next generation sequencing, Variant ranking, Human genetics, Molecular diagnostic,
Mutation detection, Annotation, Software, Barcode
INTRODUCTION
In recent years, high throughput sequencing has generated thousands of new genomes
from various species across the tree of life and millions of genetic variants. Especially
in the field of human genetics, targeted or whole exome and genome sequencing are
becoming standard assays (Ng et al., 2010; Ng et al., 2009; Saunders et al., 2012) to identify
causal single-nucleotide variations (SNVs) as well as short insertions/deletions (indels)
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Figure 1 High throughput sequencing data analysis workflow and VaRank positioning.
in patients with Mendelian diseases, or variants associated to increased disease risk (Cirulli
& Goldstein, 2010; Manolio et al., 2009).
The classical data workflow in next generation sequencing includes several bioinfor-
matics steps from the raw sequencing data analysis which transforms the signal from
the sequencers (e.g., fluorescence, pH. . . ) to raw sequences that are further aligned
to the reference genome. Sequence differences from the reference genome (variants)
are then detected aiming at identifying causal mutation (Fig. 1). Although sequencing
limitations are overcome with increasing instrument capacity (Glenn, 2011 and http://
www.molecularecologist.com/next-gen-fieldguide-2014/), the development of bioinfor-
matics solutions for variant prioritization remains a great challenge. The focus on high
throughput sequencing resulted in the development of a variety of tools, protocols and ap-
plications including variant filtering and ranking (for a review see Bao et al., 2014). Recent
approaches include the use of additional data such as haploinsufficiency prediction and
phenotype information (Sifrim et al., 2013), cross species phenotype information (Robin-
son et al., 2014) or interaction data (Smedley et al., 2014) to enhance the analysis. However,
molecular biologists still require simple tools in the variant filtering and ranking process to
identify causal mutations among a large pool of rare variants existing in each individual.
Here we propose a new simple and powerful tool named VaRank (http://www.lbgi.
fr/VaRank) for human variant ranking which provides a comprehensive workflow for
annotating and ranking SNVs and indels. Four modules create the strength of this
workflow (Fig. 2): (i) Data integration with variant call quality summary, to filter out
false positive calls, depending on the sequencing technology and the analysis pipeline; (ii)
Variant annotation to integrate genetic and predictive information (functional impact,
putative effects in protein coding regions, population frequency, phenotypic features. . . )
from different sources, using HGVS nomenclature (Taschner & den Dunnen, 2011);
(iii) Presence/absence of variants (with homozygote/heterozygote status) within all
samples represented in a barcode, to search for recurrence between families or group of
individuals and (iv) Prioritization, to score and rank variants according to their predicted
pathogenic status.
VaRank can substantially reduce the number of potential causal variants to be manually
inspected for further studies and increase the efficiency of sequence analysis for researchers
and clinicians. VaRank has been already successfully applied in the field of human genetics,
first in research including identification of new genes responsible for rare human disease
and second in diagnostics to identify mutation in known human disease implicated genes.
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Figure 2 VaRank’s workflow. The work flow is separated into 4 major steps, (i) Sequencing data
from a single or from multiple VCF files are integrated including variant call quality summary, (ii)
Annotation of each variant including genetic and predictive information (functional impact, putative
effects in protein coding regions, population frequency, phenotypic features. . . ) from different sources.
The annotation can either be done by Alamut Batch or SnpEff. (iii) Presence/absence of variants (with
homozygote/heterozygote status) within all samples represented in a barcode, and (iv) Prioritization, to
score and rank variants according to their predicted pathogenic status. The final output files are available
for each samples.
In this work we describe VaRank as a tool and how it is implemented but also present how
it was used in several real datasets.
IMPLEMENTATION
VaRank is written in Tcl/Tk and runs on all Unix platforms with a standard Tcl/Tk 8.5
installation and one of the compatible annotation engines (Alamut Batch, a commercial
software developed by Interactive Biosoftware, Rouen, France, or SnpEff (Cingolani et al.,
2012)). PolyPhen-2 (Adzhubei et al., 2010) can also be installed locally and results can be
automatically integrated into VaRank.
Input and output
To run VaRank, the user specifies the input files and chosen options with a single
command. In case of wrong commands, VaRank will print a description of the options
and defaults settings.
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VaRank reads SNV and indel variant descriptions from a VCF file (variant call format
Danecek et al., 2011), the reference format for genomic variants. The VCF file can be gzip
compressed. The program can take any combination of a single VCF file with multiple
patients and/or multiple VCF files with single patient’s data as input (Fig. 2).
Each variant is checked for consistency (genotype, depth of coverage, variant call
especially for indels) and VaRank prints warnings if appropriate (i.e., patients redundancy
based on the sample identifiers in the VCFs), information from each analysis step
(including status and running time), as well as statistics on the submitted data such as
total number of variants and number of patients.
The output from VaRank is presented in an easily-accessible tab-separated file that can
be opened in any spreadsheet program. Output files report one variant per line. Never-
theless, two types of rankings are provided: one presenting each variant independently,
ordered from most likely pathogenic to least likely pathogenic (files with “byVar” suffix),
and another ranking genes from most likely causative to least likely causative (files with
“byGene” suffix). For the latter, each gene is scored along two criteria: (i) based on its
homozygous most pathogenic variant, or (ii) based on its first two heterozygous most
pathogenic variants. In order to make sure that no variants are overlooked by the user (by
only displaying the most pathogenic variants) all other gene variants are also reported.
The “byVar” file is more appropriate for analyzing patient’s data under the dominant
or pseudominant hypothesis, while the “byGene” file is more appropriate for recessive
diseases (especially for compound heterozygous cases).
Each of these output files is also available in two versions: one contains all submitted
variants (“AllVariants” files) while the other one is prefiltered (“filteredVariants” files). The
default filters remove variants: (i) called with a read depth <= 10, (ii) with a supporting
read count <= 10, (iii) with a ratio of supporting reads <= 15%, (iv) with a validated
status annotation in the dbSNP (Sherry et al., 2001) database (based on at least two
supporting evidences) that are not pathogenic (based on the ClinicalSignificance field),
and (v) with an allele frequency>1% (extracted from the dbSNP database or the Exome
Variant Server). All these parameters can be modified by the user.
Finally, a short report of counts (homozygous, heterozygous and total counts) for each
of the variant categories (5′ and 3′ UTR, upstream, downstream, frameshift, in-frame,
nonsense, splice site, start loss, stop loss, missense, synonymous, intronic, not annotated)
is generated for each sample and for the whole submitted dataset.
Variant annotation
The annotation of variants is performed by the annotation engine (Fig. 2). It is composed
of several parts including the main annotation software, which can be either Alamut
Batch or SnpEff, the barcode annotation (see Fig. 3 and corresponding section) and
optionally PolyPhen-2 predictions. As an example, Alamut Batch collects among others
(Table 2): the gene symbol, the OMIM ID, the transcript ID (i.e., RefSeq), the protein
IDs (RefSeq and UniProt), the HGVS nomenclature (genomic, cDNA and proteic),
information from public variation databases such as dbSNP and the Exome Variant Server
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Figure 3 Barcode. (A) The barcode represents the SNV’s zygosity status in an ordered list of samples.
Samples that are homozygous for the reference allele are represented using “0,” heterozygous variants
are represented using “1” and homozygous variants are represented with “2.” (B) Selected annotations
from the VaRank output representing 3 variants from a single patient. The barcode gives an overview
of the presence/absence of one variant in all other patients analyzed. The family barcode gives a user
ordered view of the presence/absence of one variant in a selection of patients. Together with this, the
total counts of alleles are given in the last 4 columns. (C) Example of pedigrees and barcodes that can be
specifically used in family analyses such as trio exome sequencing. On the left, homozygous mutations
in a consanguineous family could be highlighted by the “121” barcode indicating homozygous variants
(“2”) in the proband inherited from heterozygous parents (“1”). On the right de novo variants in the
proband could be highlighted with the proposed barcode “010.”
(EVS, http://evs.gs.washington.edu/EVS/) and predicted effects at both nucleotide
and protein levels. When available, known mutations are highlighted by extracting
either reported SNVs/indels flagged as “probably-pathogenic”/“pathogenic” in the
field “Clinical significance” introduced since dbSNP134 or using the HGMD database
(Stenson et al., 2014).
The choice of transcript is a critical task that can lead to misannotation (McCarthy et
al., 2014). To avoid underestimating variant effects, they are annotated on all transcripts
available (i.e., one variant can be either intronic or exonic depending on the isoform) and
the most pathogenic effect is retained. Given that VaRank is compatible with 2 annotation
software there are small differences. Using Alamut Batch, each variant is scored for each
transcript. By default we report the longest transcript for each gene except if any variation
is more pathogenic in another transcript. In the case of SnpEff, the annotations are already
sorted from the most to the least pathogenic.
In order to further enrich the annotation for each variant and each gene, VaRank can
integrate (using the option -extann) external annotations provided by the user as a tab
separated file. One could for instance associate private expression data or transmission
mode for each gene of interest.
Annotating and analyzing several individuals together can be very computationally
effective since most of the variants are common polymorphisms. As an example, looking
at 180 patients sequenced for 217 genes, a total of 204,625 variations could be identified
where only 9,378 were non redundant. In this case, the separate annotation of each
patient’s variant set would have required ∼20× times the computational cost of the
combined analysis. Although the total number of non-redundant variants does not
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Figure 4 Distribution of variants in 180 patients for 217 genes. The gray line represents the distribution
of the number of variants identified in each sample in a cohort of 180 patients sequenced for 217 genes.
The dark line represents the cumulative number of non-redundant (NR) variants in the same dataset due
to each new sample added.
plateau, each new sample adds only a very limited number of new variants to the analysis
(Fig. 4).
Variant ranking
The observed variants (SNVs/indels) can be characterized at different levels (DNA, RNA
and protein levels) that VaRank aims at summarizing into a single score. This score is
then used to rank variants based on their predicted pathogenicity and thus accelerates
identification of relevant ones by biologists. The aim of this score is not to provide yet
another score to assess the pathogenicity of each variant but a rationale to present the most
relevant variants according to the biologist common use and interpretation rules. Thus,
the relative weights of each score components were determined experimentally to best
separate categories. VaRank uses the variation type (i.e., substitution, deletion, insertion,
duplication) and the coding effect to score. The VaRank scoring is categorized from the
most likely to the less likely pathogenic state as follows (score in parenthesis): known
mutation (110), nonsense (100), frameshift (100), start loss (80), stop loss (80), missense
(50), in-frame (40) and synonymous coding (10) (Table 1).
In addition when using Alamut Batch, each variant is assessed for any potential effect on
the nearest splice site. Following the guidelines from Houdayer et al. (2012) and our own
tests (data not shown), we selected three assessment programs: MaxEntScan (Yeo & Burge,
2004), NNSplice (Reese et al., 1997) and Splice Site Finder (based on Shapiro & Senapathy,
1987). A variant is considered to affect splicing when at least two out of the three programs
indicate a significant score change between the wild type and the mutated sequences
(respectively−10%,−5% and−15%). A VaRank score is then attributed depending on the
following three splice site categories (score into parenthesis): (i) essential splice site: two
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Table 1 Scoring scheme description. Scores in bold reflect score values after the adjustment score is applied.
Variant category Option name VaRank score Definitions
Known mutation S Known 110 Known mutation as annotated by HGMD and/or dbSNP (rsClinical-
Significance= “pathogenic/probable-pathogenic”).
Nonsense S Nonsensea 100, 105 A single-base substitution in DNA resulting in a STOP codon
(TGA, TAA or TAG).
Frameshift S Fs 100 Exonic insertion/deletion of a non-multiple of 3bp resulting often in a
premature stop in the reading frame of the gene.
Essential splice site S EssentialSplicea 90, 95 Variation in one of the canonical splice sites resulting in a significant
effect on splicing.
Start loss S StartLossa 80, 85 Variation leading to the loss of the initiation codon (Met).
Stop loss S StopLossa 80, 85 Variation leading to the loss of the STOP codon.
Intron-exon boundary S CloseSplicea 70, 75 Variation outside of the canonical splice sites (donor site is−3 to+6,
acceptor site−12 to+2).
Missense S Missensea,b 50, 55, 60, 65 A single-base substitution in DNA not resulting in a change in the
amino acid.
Indel in-frame S Inframe 40 Exonic insertion/deletion of a multiple of 3bp.
Deep intron-exon boundary S DeepSplicea 25, 30 Intronic variation resulting in a significant effect on splicing.
Synonymous coding S Synonymousa 10, 15 A single-base substitution in DNA not resulting in a change in the
amino acid.
Notes.
a Each variant score is adjusted (+5) if high conservation at the genomic level is observed (phastCons cutoff>0.95).
b Missense scores are adjusted (+5) for each deleterious prediction (SIFT and/or PPH2).
first intronic bases up- or downstream the exon (90), (ii) intron-exon boundary: donor
site from−3 to+6, acceptor site from−12 to+2 (70) and (iii) deep intronic changes (25).
It should be noted that a SNV affecting the first or last base of an exon can either have a
coding effect as a missense or an effect on splicing. VaRank reports the most pathogenic of
these two possible effects.
If appropriate the variant score is further adjusted using additional information
as nucleotide-level conservation (phastCons Siepel et al., 2005) and protein-level
pathogenicity predictions (SIFT and PolyPhen-2) (Adzhubei et al., 2010; Kumar, Henikoff
& Ng, 2009) that are used to compute an adjustment score (0 or +5) to be added to the
relevant category (Table 1).
Barcode
Comparing variations of several individuals, related and/or unrelated, affected or not,
has proven to be a very effective strategy for distinguishing polymorphisms from variants
causing or increasing the likelihood of disease (Ng et al., 2010; Ng et al., 2009). In order
to take advantage of this, VaRank introduces a barcode that allows a quick overview of
the presence/absence status of each variant within all samples and their zygosity status
(“0” representing homozygous wild type, “1” heterozygous and “2” homozygous for the
variant) (Fig. 3A). In Fig. 3B, three variants are reported for one specific patient out of
a cohort of 32 samples analyzed together. For example, the third variation c.601G>A
in TTC21B is heterozygous for this patient. In light of the presented barcode, one can
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Table 2 Summary description of the annotations provided by VaRank using Alamut Batch.
Column name Annotation
VariantID Variant identifier [#chr] [genomicposition] [RefBase] [VarBase]
Gene Gene symbol
omimId OMIM® id
TranscriptID RefSeq transcript id
TranscriptLength Length of transcript (full cDNA length)
Chr Chromosome of variant
Start Start position of variant
End End position of variant
Ref Nucleotide sequence in the reference genome (restricted to 50bp)
Mut Alternate nucleotide sequence (restricted to 50bp)
Uniprot Uniprot
protein Protein id (NCBI)
posAA Amino acid position
wtAA 1 Reference codon
varAA 1 Alternate codon
Phred QUAL QUAL: The Phred scaled probability that a REF/ALT polymorphism exists at this site given sequencing
data. Because the Phred scale is−10 * log(1− p), a value of 10 indicates a 1 in 10 chance of error, while
a 100 indicates a 1 in 10ˆ 10 chance. These values can grow very large when a large amount of NGS data
is used for variant calling.
HomHet Homozygote or heterozygote status
TotalReadDepth Total number of reads covering the position
VarReadDepth Number of reads supporting the variant
%Reads variation Percent of reads supporting variant over those supporting reference sequence/base
VarType Variant Type (substitution, deletion, insertion, duplication, delins)
CodingEffect Variant Coding effect (synonymous, missense, nonsense, in-frame, frameshift, start loss, stop loss)
VarLocation Variant location (upstream, 5’UTR, exon, intron, 3’UTR, downstream)
Exon Exon (nearest exon if intronic variant)
Intron Intron
gNomen Genomic-level nomenclature
cNomen cDNA-level nomenclature
pNomen Protein-level nomenclature
rsID dbSNP variation
rsValidation dbSNP validated status
rsClinicalSignificance dbSNP variation clinical significance
rsAncestralAllele dbSNP ancestral allele
rsHeterozygosity dbSNP variation average heterozygosity
rsMAF dbSNP variation global Minor Allele
rsMAFAllele dbSNP variation global minor allele
rsMAFCount dbSNP variation sample size
1000g AF 1,000 genomes global allele frequency
1000g AFR AF 1,000 genomes allele frequency in African population
1000g SAS AF 1,000 genomes allele frequency in South Asian population
1000g EAS AF 1,000 genomes allele frequency in East Asian population
(continued on next page)
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Table 2 (continued)
Column name Annotation
1000g EUR AF 1,000 genomes allele frequency in European population
espRefEACount ESP reference allele count in European American population
espRefAACount ESP reference allele count in African American population
espRefAllCount ESP reference allele count in all population
espAltEACount ESP alternate allele count in European American population
espAltAACount ESP alternate allele count in African American population
espAltAllCount ESP alternate allele count in all population
espEAMAF Minor allele frequency in European American population
espAAMAF Minor allele frequency in African American population
espAllMAF Minor allele frequency in all population
espAvgReadDepth Average sample read Depth
delta MESscore (%) % difference between the splice score of variant with the score of the reference base
wtMEScore WT seq. MaxEntScan score
varMEScore Variant seq. MaxEntScan score
delta SSFscore (%) % difference between the splice score of variant with the score of the reference base
wtSSFScore WT seq. SpliceSiteFinder score
varSSFScore Variant seq. SpliceSiteFinder score
delta NNSscore (%) % difference between the splice score of variant with the score of the reference base
wtNNSScore WT seq. NNSPLICE score
varNNSScore Variant seq. NNSPLICE score
DistNearestSS Distance to Nearest splice site
NearestSS Nearest splice site
localSpliceEffect Splicing effect in variation vicinity (New donor Site, New Acceptor Site, Cryptic Donor Strongly
Activated, Cryptic Donor Weakly Activated, Cryptic Acceptor Strongly Activated, Cryptic Acceptor
Weakly Activated)
SiftPred SIFT prediction
SiftWeight SIFT score ranges from 0 to 1. The amino acid substitution is predicted damaging is the score is
<=0.05, and tolerated if the score is >0.05.
SiftMedian SIFT median ranges from 0 to 4.32. This is used to measure the diversity of the sequences used for
prediction. A warning will occur if this is greater than 3.25 because this indicates that the prediction
was based on closely related sequences. The number should be between 2.75 and 3.5
PPH2pred PolyPhen-2 prediction using HumVar model are either “neutral, possibly damaging, probably damag-
ing” or “neutral, deleterious” depending on the annotation engine.
phyloP phyloP
PhastCons PhastCons score
GranthamDist Grantham distance
VaRank VarScore Prioritization score according to VaRank
AnnotationAnalysis Yes or No indicates if the variation could annotated by any annotation engine
Avg TotalDepth Total read depth average at the variant position for all samples analyzed that have the variation
SD TotalDepth Standard deviation associated with Avg TotalDepth
Count TotalDepth Number of samples considered for the average total read depth
Avg SNVDepth Variation read depth average at the variant position for all samples analyzed that have the variation
SD SNVDepth Standard deviation associated with Avg SNVDepth
Count SNVDepth Number of samples considered for the average SNV read depth
(continued on next page)
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Table 2 (continued)
Column name Annotation
familyBarcode Homozygote or heterozygote status for the sample of interest and its associated samples
Barcode Homozygote or heterozygote status for all sample analyzed together (Hom: 2; Het: 1; Sample name is
given at the first line of the file: ## Barcode)
Hom Count Number of homozygote over all samples analyzed together
Het Count Number of heterozygote over all samples analyzed together
Allele Count Number of alleles supporting the variant
Sample Count Total number of samples
immediately notice that the variant is also present in 28 other samples from the cohort, of
which in total 12 are homozygous and 17 heterozygous.
In order to allow inheritance analysis, a second barcode (the family barcode) represent-
ing only user selected samples can be defined. As an example in trio exome sequencing,
we have represented two typical pedigrees (Figs. 3B and 3C), one consanguineous family
on the left and one sporadic case on the right. In the case of consanguinity, homozygous
mutations are often the cause of the disease in the family. This could be highlighted by
selecting the “121” barcode indicating homozygous variants (“2”) in the proband inherited
from heterozygous parents (“1”). In the sporadic case, several hypotheses could be tested
including a de novo variant which could be highlighted using the barcode “010.”
Together with the barcode, simple counts on the individuals (homozygous, heterozy-
gous and total allelic counts) are also available and can easily be used to further filter
variants. Indeed, in rare diseases such as the Bardet-Biedl syndrome (BBS, OMIM#
209900), mutations are often private (i.e., one mutation found only in one family) (Muller
et al., 2010) meaning that their frequency in the population is very low. Counts can be used
to estimate the frequency of a known variant in the user cohort and add significant value
to variants not yet reported in any public variant database but for which a frequency can be
estimated based on the user’s cohort. As an example, looking at 2,888 non redundant SNVs
observed in 107 patients with moderate to severe intellectual disability, 979 did not have
any frequency information in the dbSNP and EVS databases. Such information could be
directly retrieved from the VaRank output.
The observed frequency of variants in public databases but also in private cohorts can
be a powerful filtering strategy. Using the same data (Fig. 3B), variant c.7911dup in ALMS1
is present only once in the cohort of patients at the homozygous state and is very likely the
disease causing mutation in this patient.
RESULTS AND DISCUSSION
VaRank was successfully applied in various human genetics studies both in diagnostics and
research. In total, more than 800 patients from several datasets of increasing complexity
including the Cockayne syndrome (10 genes tested, manuscript in preparation),
Bardet-Biedl syndrome (30 genes (Redin et al., 2012)), ataxias (60 genes), leucodystrophies
(70 genes, manuscript in preparation), congenital myopathies (142 genes (Vasli et al.,
2012) and 275 genes, manuscript in preparation), intellectual disability (217 genes,
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Redin et al., 2014) and exome sequencing (Scheidecker et al., 2014) have been analyzed
to highlight potential pathogenic variants.
In the following sections, we will provide insight into several datasets analyzed by
VaRank and that were used to validate the tool and to highlight its effectiveness. All the
input files and output files from the following datasets are available online (www.lbgi.fr/
VaRank).
Bardet-Biedl syndrome (BBS) dataset
The Bardet-Biedl syndrome (BBS; OMIM# 209900) is a pleiotropic recessive disorder,
part of the ciliopathies, characterized by extensive genetic heterogeneity counting to
date 19 genes (Aldahmesh et al., 2014; Scheidecker et al., 2014). We applied targeted high-
throughput sequencing for 30 ciliopathy related genes to 52 patients with clinical features
compatible with BBS (Redin et al., 2012). VaRank was used to annotate and rank the vari-
ants identified in those patients. Thirty-two cases could be solved by this approach leading
to frameshift, missense and splice site mutations all validated by Sanger sequencing (we ex-
cluded Copy Number Variations). Sequencing data from the 32 positive samples have been
reanalyzed using Alamut Batch version 1.1.11 and PolyPhen-2 v2.2.2 installed on our local
servers. A total of 784 non redundant variants have been annotated resulting on average
into 167 private variants per sample. We extracted the validated mutations and highlighted
the ranking position in the output files (Table 3). In 30/32 samples, mutations were ranked
first, while in the remaining ones they were present in the top five among∼170 variants per
patient. This result clearly shows the effectiveness of the ranking in such situation.
As mentioned in the original paper, one variant is always ranked in first position and
represents a false positive described in BBS2 as a third allele mutation according to the
triallelic hypothesis (NM 031885.3:c.209G>A, rs4784677). It is flagged as pathogenic in
dbSNP, but it is too frequent to be a fully penetrant mutation according to the observed
frequency in the Exome Variant Server (EVS) (0.77%). Interestingly, using the barcode
this variant is very easily filtered out since it is present in almost all patients in our cohort
(31/32 samples).
Intellectual disability (ID) dataset
Intellectual disability is a common neurodevelopmental disorder (∼2% of children and
adolescents) (Ellison, Rosenfeld & Shaffer, 2013) that can be initiated by either environ-
mental, genetic or multifactorial causes. The monogenic forms are very heterogeneous
genetically, with several hundred genes identified so far. We present here the results of 203
patients affected with moderate to severe intellectual disability.
A first cohort of 107 patients was already analyzed by VaRank (Redin et al., 2014) and led
to the identification of 25 causal mutations (Table 4A). A second cohort of 96 additional
patients is reported here for which 12 causative mutations could be identified (Table 4B).
The identified mutations were all validated by Sanger sequencing (we excluded pathogenic
CNV). High-throughput sequencing data of protein-coding exons of 217 genes (first
cohort) and 275 genes (second cohort) (either on the X-chromosome or associated to
autosomal dominant or recessive forms of ID) were collected for the 25 positive known
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Table 3 Analysis of 32 patients with Bardet-Biedl syndrome. From the BBS dataset, mutations and ranking for 32 patients sequenced for 30 genes. The ranking for
each mutation has been obtained from the “filteredVariants” output. Mutations in italics are predicted to affect splicing.
Patient# Gene RefSeq Mutation (cDNA) Mutation (protein) Ranking
P11 c.[436C>T];[436C>T] p.[R146*];[R146*] Rank 1
ALD6a c.[436C>T];[(592-?) (830+?)del] p.[R146*];[ ?] Rank 1
ALO47 c.[479G>A];[479G>A] p.[R160Q];[R160Q] Rank 1
AIO57 c.[670G>A];[670G>A] p.[E224K];[E224K] Rank 1
AMK19 c.[951+1G>A];[1169T>G] p.[?];[M390R] Rank 1, Rank 2
P9 c.[1110G>A];[1110G>A] p.[ ?];[ ?] Rank 1
AKH61 c.[1169T>G];[1169T>G] p.[M390R];[M390R] Rank 1
P1 c.[1471+4G>A]; [1471+4G>A] p.[?];[?] Rank 2c
AHZ63b
BBS1 NM 024649.4
c.[1473+4T>A];[=] p.[?];[=] Rank 1
AGA99 c.[118-1G>C];[118-1G>C] p.[ ?];[ ?] Rank 1
P2 c.[345+5G>A];[345+5G>A] p.[?];[?] Rank 1
P7 c.[565C>T];[565C>T] p.[R189*];[R189*] Rank 1
ALG76 c.[626T>C];[626T>C] p.[L209P];[L209P] Rank 1
AKX44 c.[814C>T];[814C>T] p.[R272*];[R272*] Rank 1
AGL23
BBS2 NM 031885.3
c.[1992delT];[1992delT] p.[H665Tfs*675];[H665Tfs*675] Rank 1
P13 c.[149T>G];[149T>G] p.[L50R];[L50R] Rank 1
ALG5
BBS5 NM 152384.2
c.[413G>A];[413G>A;] p.[R138H];[R138H] Rank 1
AIZ46 c.[3G>A];[110A>G] p.[M1I];[Y37C] Rank 1, Rank 2
AIZ62 c.[571G>T];[724G>T] p.[E191*];[A242S] Rank 1, Rank 2
P10
MKKS NM 018848.3
c.[1272+1G>A];[1272+1G>A] p.[?];[?] Rank 1
ALB60 BBS9 NM 198428.2 c.[855del];[855del] p.[W285*];[W285*] Rank 1
ALS67 c.[271 272insT];[728 731delAAGA] p.[C91Lfs*95];[K243Ifs*257] Rank 1, Rank 2
AMA70 c.[271 272insT];[1201G>T] p.[C91Lfs*95];[G401*] Rank 1, Rank 2
JSL c.[285A>T];[2119-2120delGT] p.[R95S];[V707*fs] Rank 1, Rank 2
P8 c.[1181 1182insGCATTTAT];[1181 1182insGCATTTAT] p.[S396Lfs*401];[S396Lfs*401] Rank 1
AMR64 c.[1241T>C];[1241T>C] p.[L414S];[L414S] Rank 1
AKR68
BBS10 NM 024685.3
c.[1241T>C];[1241T>C] p.[L414S];[L414S] Rank 2
ALP79 BBS12 NM 001178007.1 c.[865G>C];[205C>T(;)1859A>G] p.[A289P];[L69F(;)Q620R] Rank 1, Rank 2
ALB64 c.[1724C>G];[1724C>G] p.[S575*];[S575*] Rank 1
AIA84 c.[3340del];[3340del] p.[E1112Rfs*1120];[E1112Rfs*1120] Rank 1
ADC44 c.[7904insC];[7904insC] p.[N2636Qfs*59];[N2636Qfs*59] Rank 1
AKO26
ALMS1 NM 015120.4
c.[10879C>T];[10879C>T] p.[R3627*];[R3627*] Rank 1
Notes.
a The second mutation of the patient, a complete heterozygous deletion of exon 8 and 9 (c.(592-?) (830+?)del) is a pathogenic CNV that cannot be ranked by VaRank.
b Parent of BBS patients, a single heterozygous mutations is expected.
c This validated mutation was filtered out in the “filteredVariants” results due to low sequencing quality (only 7 reads supported the variant) but ranked at the second position in the non-filtered
results.
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Table 4 Analysis of 203 patients with intellectual disability. (A) Mutations and ranking in the 25 positive patients from the 107 patients sequenced
for 217 genes (Redin et al., 2014). (B) Mutations and ranking from 12 novel positive patients with ID identified in an additional cohort of 96 patients
screened for 275 genes. Patients are sorted according to the mode of inheritance and the identified gene. Known mutations (from the literature)
are highlighted in bold. Ranking into parenthesis highlights the ranking of the variations with a similar score. Mode of inheritance include: AD,
autosomic dominant; AR, autosomic recessive; XL, X-linked; XLD, dominant on the X chromosome.
(A)
Patient# Sex Gene Chromosome Mode of
inheritance
Mutation (cDNA) Mutation (protein) Ranking
APN-58 M c.[613C>T];[=] p.[R205*];[=] Rank 2
APN-87 M
DYRK1A 21 AD
c.[621 624delinsGAA];[=] p.[E208Nfs*3];[=] Rank 1
APN-63 M GRIN1 9 AD c.[1733C>G];[=] p.[P578R];[=] Rank 1 (2)
APN-14 M MED13L 12 AD c.[6118 6125del];[=] p.[G2040Nfs*32];[=] Rank 1 (2)
APN-46 M RAI1 17 AD c.[2332 2336del];[=] p.[G778Efs*7];[=] Rank 1
APN-122 F SHANK3 22 AD c.[2955 2970dup];[=] p.[P992Rfs*325];[=] Rank 1
APN-38 M SLC2A1 1 AD c.[724C>T];[=] p.[E242*];[=] Rank 2
APN-139 M SYNGAP1 6 AD c.[3583-6G>A];[=] p.[?];[?] Rank 1
APN-41 M c.[514 517del];[=] p.[K172Ffs*61];[=] Rank 1
APN-117 F
TCF4 18 AD
c.[520C>T];[=] p.[R174*];[=] Rank 1
APN-138 M ATRX X XL c.[109C>T];[0] p.[R37*];[0] Rank 1 (2)
APN-137 M CUL4B X XL c.[811 812del];[0] p.[E271Aspfs*11];[0] Rank 1 (2)
APN-42 M DMD X XL c.[10889del];[0] p.[R3630Efs*27];[0] Rank 1
APN-113 M HCFC1 X XL c.[218C>T];[0] p.[A73V];[0] Rank 1
APN-82 M IL1RAPL1 X XL c.[894 903del];[0] p.[W299Tfs*18];[0] Rank 1
APN-68 M IQSEC2 X XL c.[3097C>T];[0] p.[E1033*];[0] Rank 1 (2)
APN-34 M c.[2152G>C];[0] p.[A718P];[0] Rank 1
APN-135 M
KDM5C X XL
c.[1296dup];[0] p.[E433*];[0] Rank 1
APN-16 M MAOA X XL c.[797 798delinsTT];[0] p.[C266F];[0] Rank 1
APN-130 F c.[952C>T];[=] p.[R318C];[=] Rank 2a
APN-142 F
MECP2 X XLD
c.[538C>T];[=] p.[R180*];[=] Rank 1a
APN-105 M PHF8 X XL c.[1249+5G>C];[0] p.[Y406Ffs*24];[0] Rank 4
APN-43 M SLC9A6 X XL c.[526-9 526-5del];[0] p.[?];[0] Rank 1
APN-110 M SLC16A2 X XL c.[1412T>C];[0] p.[L471P];[0] Rank 1
(B)
Patient# Sex Gene Chromosome Mode of
inheritance
Mutation (cDNA) Mutation (protein) Ranking
APN-206 F ANKRD11 16 AD c.[2904del];[=] p.[Glu969Argfs*8];[=] Rank 1 (2)
APN-237 F DYRK1A 16 AD c.[1205dup];[=] p.[Arg404Thrfs*10];[=] Rank 1 (2)
APN-176 F FOXG1 14 AD c.[755G>T];[=] p.[Gly252Val];[=] Rank 2 (3)
APN-188 F MBD5 2 AD c.[3949del];[=] p.[Gln1317Serfs*48];[=] Rank 1
APN-211 M MED13L 12 AD c.[2340 2343de];[=] p.[Thr781Metfs*19];[=] Rank 1 (2)
APN-200 M SYNGAP1 6 AD c.[1717C>T];[=] p.[Arg573Trp];[=] Rank 2
APN-226 F TBR1 3 AD c.[713 719del];[=] p.[Ser238Thrfs*17];[=] Rank 2 (2)
APN-149 M c.[990G>A];[=] p.[?];[=] Rank 1
APN-214 M c.[1726C>T];[=] p.[Arg576*];[=] Rank 2
APN-210 F
TCF4 18 AD
c.[1733G>A];[=] p.[Arg578His];[=] Rank 2 (2)a
APN-209 F ASPM 1 AR c.[2967G>A];[ 6920 6921del] p.[Trp989*];[Gln2307Leufs*10] Rank 1, Rank 2
APN-162 M KIAA2022 X XL c.[2725del];[0] p.[Ala909Profs*13];[0] Rank 1
Notes.
a Known mutation not annotated as pathogenic in dbSNP.
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patients and the 96 additional ones. A total of 8,388 non redundant variants have been
reannotated by VaRank using Alamut Batch version 1.1.11 and PolyPhen-2 v2.2.2,
resulting on average into 1,129 (±189) private variants per sample. Each sample has been
reanalyzed and a summary of the ranking results using the default filtration strategy for
this dataset defined by the biologists (frequency in dbSNP or EVS >1% and presence
in <3 samples) is available in Table 4. Among the 37 patients with causative mutations
identified almost all were ranked first or within the top five among 1,129 variants on
average demonstrating the usefulness of this strategy.
As an example, in a boy with autism spectrum disorder, attention deficit and
autoaggressive behavior, one mutation (c.797 798delinsTT, p.C266F) has been observed in
the MAOA gene. A total of 688 variants have been annotated by VaRank and the mutation
described for this patient could be ranked without filtering at position 8. When the usual
filters are applied (frequency in dbSNP or EVS >1%), the mutation is ranked at the first
position in the “filteredVariants.rankingByVar.txt” file. This result was the first mutation
report in the MAOA gene since 20 years (Piton et al., 2014).
Whole Exome Sequencing (WES) dataset
WES of a single patient with a clear BBS phenotype from a consanguineous Italian family
(Scheidecker et al., 2014) revealed for the first time mutations in the BBIP1 gene counting
since as the 18th BBS gene. A total of 50,569 non redundant variants have been annotated
by VaRank using Alamut Batch version 1.1.11 and PolyPhen-2 v2.2.2.
The nonsense mutation c.173T>G (p.Leu58*) in BBIP1 has been ranked at the 50th
position/50569 in the “allVariants.rankingByVar” file. Applying the default filtration
strategy (i.e., frequency in dbSNP or EVS >1% and sequence quality filters) changed
the ranking to the 6th position/4,908 (“filteredVariants.rankingByVar” file). This exome
sequencing dataset was analyzed together with 29 other exomes from unrelated patients
and pathologies for a BBS patient for which we could further filter variations using for
example the barcode. Given that the most frequent known disease causing mutation in BBS
is the c.1169T>G (p.M390R) mutation in BBS1 (Mykytyn et al., 2002), found in EVS at
the frequency of 26/12,694 (0.2%) at the heterozygous state, we used the barcode statistics
to further reduce the total number of variations. Being very tolerant, we kept variants
present less than four times at the heterozygous state or two times at the homozygous state
out of 29 samples. The final ranking placed the mutation at the forth position (and first
homozygous) out of 3,493 remaining variants.
The integration of these three datasets of increasing complexity (BBS with 30 genes
consolidated on 188 patients, ID with more than 200 genes in 121 patients and the WES
data consolidated for 35 samples) highlights major directions for further developments.
Considering the distribution of the non-redundant variation by functional category,
one can first observe, despite a different gene composition, that the distribution of the
categories is similar among the datasets (Fig. 5). The vast majority of the identified and
annotated variations are either intronic or synonymous. Those categories contain known
variations in dbSNP (∼85% have an rs#) and are either polymorphisms or rare variant.
Geoffroy et al. (2015), PeerJ, DOI 10.7717/peerj.796 14/20
Figure 5 Representation of the non-redundant variations by functional type in 3 datasets. The chart
is built upon the Intellectual disability (ID) and Bardet-Biedl Syndrome (BBS) (consolidated from
188 patients addressed for BBS) datasets discussed in the Results section together with an enhanced
exome dataset (35 exomes). The “truncating” category corresponds to frameshift, nonsense, stoploss and
startloss.
Thus they are often considered as non-pathogenic. Nevertheless, some of these could
potentially affect the correct splicing of the closest gene. Although efforts are being taken
to enhance the predictions on splicing especially for the consensus sequences (Houdayer
et al., 2012; Jian, Boerwinkle & Liu, 2014), little is done in more distant regions including
enhancers sequences, branch point or even promoter regions. The 5’ and 3’ UTRs are
also sources of variations that are often overlooked but contain important functional
signals such as miRNA binding sites and polyadenylation signal (Chatterjee & Pal, 2009).
Missenses are one of the major variations sources and also one of the more difficult to
interpret. There is a high number of predictions methods and tools available aiming at
predicting the pathogenicity of this category of variant but there is still improvement
to be made (Flanagan, Patch & Ellard, 2010; Hicks et al., 2011; Tavtigian et al., 2008).
Recent approaches aimed at combining knowledge based information such as structural
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information for missense variants (Luu et al., 2012) or focusing only on orthologous
sequences (Wong & Zhang, 2014). Other interesting annotation sources might be included
as the assessment of non-frameshift indels (Bermejo-Das-Neves et al., 2014; Hu & Ng,
2012) and the consideration of CNVs to improve the decision-making. Those issues will be
amplified using whole genome sequencing (WGS).
CONCLUSION
The rationale behind VaRank is to provide a simple yet powerful tool for biologists and
researchers aiming to discover new human disease causing variants (i.e., mutations)
from DNA sequencing projects. VaRank is a comprehensive workflow for annotating
and ranking SNVs and indels that aims at collecting the major annotation sources. The
program is currently compatible with two annotation software namely Alamut Batch
and SnpEff. This could further expanded to other annotation solutions such as Annovar
(Wang, Li & Hakonarson, 2010) or VEP (McLaren et al., 2010). It stands out from other
solutions by being able to provide a summarized overview of the presence/absence status
of each variant within all patients (e.g., barcode and family barcode) and allowing users to
easily test several disease transmission hypothesis (recessive, dominant. . . ). The barcode
counts can serve as an internal frequency database in order to filter out known and
unknown frequent variants together with annotation errors and recurrent sequencing
errors. Moreover, a specific ranking for each gene is particularly appropriate in the case of
recessive diseases. Finally, as a command line tool it can easily be integrated into existing
bioinformatics pipelines and accelerate identification of causal variants. The manual and
a tutorial together with changelogs and various use cases are available via our dedicated
website at http://www.lbgi.fr/VaRank.
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